| |
Apis
|
Vespula
|
|---|
|
Number
|
81
|
65
|
|
Age (years)*
|
42.33 ± 12.58
|
39.2 ± 13.06
|
|
[46 (18–70)]
|
[38 (17–70)]
|
|
Gender
| | |
|
Female, no (%)
|
34 (42 %)
|
33 (51 %)
|
|
Male, no (%)
|
47 (58 %)
|
32 (49 %)
|
|
Severity of systemic reactions (%)
|
|
Grade I
|
9 (11.1)
|
5 (7.7)
|
|
Grade II
|
21 (26)
|
25 (38.5)
|
|
Grade III
|
24 (29.6)
|
15 (23)
|
|
Grade IV
|
27 (33.3)
|
20 (30.8)
|
|
Patient groups for cross-sectional validation
|
|
New diagnosis
|
18 (22.2)
|
23(35.4)
|
|
Recently started (up-dosing) VIT
|
30 (37)
|
18 (27.7)
|
|
Receiving on maintenance VIT
|
22 (27.2)
|
16 (24.6)
|
|
Stopped VIT
|
11 (13.6)
|
8 (12.3)
|
- For the variables with *, cells represent mean ± standard deviation [median (min–max)], for the others, cells represent frequency (percent). VIT venom immunotherapy
